Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Patent: 7,635,695

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 7,635,695
Title:Antiinflammation agents
Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.
Inventor(s): Burkitt; Simon A. (Kirkby-in-Ashfield, GB), Cardozo; Mario G. (San Francisco, CA), Cushing; Timothy D. (Pacifica, CA), DeGraffenreid; Michael R. (San Francisco, CA), Farthing; Christopher N. (Macclesfield, GB), Hao; Xiaolin (Foster City, CA), Jaen; Juan C. (Burlingame, CA), Jiao; Xian Yun (San Mateo, CA), Kopecky; David J. (San Francisco, CA), Labelle; Marc (Burlingame, CA), Lively; Sarah E. (Congleton, GB), McMinn; Dustin L. (Pacifica, CA), Rasmussen; Sven P. (Congleton, GB), Shin; Youngsook (San Mateo, CA), Smith; Marie-Louise (Half Moon Bay, CA), Smith; Andrew (Macclesfield, GB)
Assignee: Amgen Inc. (South San Francisco, CA)
Application Number:11/709,895
Patent Claims:see list of patent claims

Details for Patent 7,635,695

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial Amgen Inc. (South San Francisco, CA) 2022-10-31 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Amgen Inc. (South San Francisco, CA) 2022-10-31 RX Orphan search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial Amgen Inc. (South San Francisco, CA) 2022-10-31 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,635,695

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2004041285 May 21, 2004
United States of America 2004097485 May 20, 2004
United States of America 2007155777 Jul 05, 2007
United States of America 7199119 Apr 03, 2007
Japan 2006512313 Apr 13, 2006
European Patent Office 1556053 Apr 19, 2006
European Patent Office 1556053 Jul 27, 2005
>Country >Patent Number >Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.